Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for sertraline
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on sertraline or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on sertraline and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed class of antidepressant, yet it is not known whether one SSRI is more effective than another.To compare the effectiveness of 3 SSRIs (paroxetine, fluoxetine, and sertraline) in depressed primary care patients.Open-label, randomized, intention-to-treat trial, with patient enrollment occurring in April-November 1999 (...) .Thirty-seven clinics in 2 US primary care research networks.A total of 573 depressed adult patients for whom their primary care physician thought that antidepressant therapy was warranted and who completed a baseline interview.Patients were randomly assigned to receive paroxetine (n = 189), fluoxetine (n = 193), or sertraline (n = 191) for 9 months. Primary care physicians were allowed to switch patients to a different SSRI or non-SSRI antidepressant if they did not adequately respond to or tolerate
Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. Despite the high prevalence, chronicity, and associated comorbidity of posttraumatic stress disorder (PTSD) in the community, few placebo-controlled studies have evaluated the efficacy of pharmacotherapy for this disorder.To determine if treatment with sertraline hydrochloride effectively diminishes symptoms of PTSD of moderate to marked severity.Twelve-week, double-blind, placebo (...) ; 73% were women; and 61.5% experienced physical or sexual assault).Patients were randomized to acute treatment with sertraline hydrochloride in flexible daily dosages of 50 to 200 mg/d, following 1 week at 25 mg/d (n=94); or placebo (n=93).Baseline-to-end-point changes in CAPS-2 total severity score, Impact of Event Scale total score (IES), and Clinical Global Impression-Severity (CGI-S), and CGI-Improvement (CGI-I) ratings, compared by treatment vs placebo groups. Results Sertraline treatment
Sertraline: a review of its therapeutic use in post-traumatic stress disorder Sertraline: a review of its therapeutic use in post-traumatic stress disorder Sertraline: a review of its therapeutic use in post-traumatic stress disorder Comer A M, Figgitt D P Authors' objectives To review the clinical efficacy and tolerability of sertraline in post-traumatic stress disorder. Searching Adisbase, MEDLINE and EMBASE were searched from 1966 to October 2000 using the terms 'sertraline' or 'CP-51974 (...) ' or 'CP-5197401' and 'post-traumatic-stress-disorder' and 'sertraline adj pk/pd'. Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug. Study selection Study designs of evaluations included in the review When available, large well-controlled trials with appropriate statistical methodology were preferred. Specific interventions included
Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. The serotonin reuptake inhibitors are the treatment of choice for patients with obsessive-compulsive disorder; however, empirical support for this assertion has been weaker for children and adolescents than for adults.To evaluate the safety and efficacy of the selective serotonin reuptake inhibitor sertraline hydrochloride in children and adolescents with obsessive-compulsive (...) disorder.Randomized, double-blind, placebo-controlled trial.One hundred eighty-seven patients: 107 children aged 6 to 12 years and 80 adolescents aged 13 to 17 years randomized to receive either sertraline (53 children, 39 adolescents) or placebo (54 children, 41 adolescents).Twelve US academic and community clinics with experience conducting randomized controlled trials.Sertraline hydrochloride was titrated to a maximum of 200 mg/d during the first 4 weeks of double-blind therapy, after which patients continued
Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. The chronic form of major depression is associated with a high rate of prevalence and disability, but no controlled research has examined the impact of long-term treatment on the course and burden of illness.To determine if maintenance therapy with sertraline hydrochloride can effectively prevent recurrence of depression in the high-risk group of patients experiencing chronic major depression (...) or major depression with antecedent dysthymic disorder ("double depression").A 76-week randomized, double-blind, parallel-group study, conducted from September 1993 to November 1996.Outpatient psychiatric clinics at 10 academic medical centers and 2 clinical research centers.Maintenance treatment with either sertraline hydrochloride (n = 77) in flexible doses up to 200 mg or placebo (n = 84).A total of 161 outpatients with chronic major or double depression who responded to sertraline in a 12-week
Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. Premenstrual dysphoric disorder is an important cause of symptoms and functional impairment in menstruating women.To evaluate the efficacy of sertraline hydrochloride for treatment of premenstrual dysphoria by measuring changes in symptom expression and functional impairment.Two screening cycles followed by 1 single (...) -blind placebo cycle and 3 cycles of randomized, double-blind, placebo treatment.Twelve university-affiliated outpatient psychiatry and gynecology clinics.Of the 447 women who requested participation, 243 met criteria for premenstrual dysphoric disorder and were randomized; 200 women completed the study.A flexible (50-150 mg) daily dose of sertraline hydrochloride.The Daily Record of Severity of Problems, Hamilton Rating Scale for Depression, Clinical Global Impression Scale, and Social Adjustment
A comparison of the cost-effectiveness of sertraline versus tricyclic antidepressants in primary care A comparison of the cost-effectiveness of sertraline versus tricyclic antidepressants in primary care A comparison of the cost-effectiveness of sertraline versus tricyclic antidepressants in primary care Forder J, Kavanagh S, Fenyo A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Sertraline (a selective serotonin re-uptake inhibitor (SSRI)) versus conventional tricyclic antidepressants (TCA) in treating depression. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Patients diagnosed and treated for depression in primary care. Depression was defined as five or more symptoms
Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization Sclar D A, Robison L M, Skaer T L, Galin R S, Legg R F, Nemec N L, Hughes T E, Buesching D P, Morgan M Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Selective Serotonin Reuptake Inhibitors (SSRIs) in antidepressant pharmacotherapy; (a) paroxetine, (b)sertraline, and (c) fluoxetine in the treatment of depression. Type of intervention
Cost utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin Cost utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin Cost utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin Hatziandreu E J, Brown R E, Revicki D A, Turner R, Martindale J, Levine S, Siegel J E Record Status This is a critical abstract of an economic (...) , recurrence and discount rates and the number of years of maintenance treatment. The method used was not specified. Estimated benefits used in the economic analysis Sertraline yielded 14.94 QALYs; Dothiepin yielded 14.13 QALYs (both were discounted using a 5% discount rate). Duration of benefits was lifetime. Cost results Lifetime costs were 3,407 for Sertraline and 1,648 for Dothiepin (both discounted at 5%) Synthesis of costs and benefits The incremental cost per Qaly gained of sertraline versus